A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 225
- Population
- ALL · 50 Years
- Duration
- 2015-09-28 to 2019-03-28
- Intervention
- Ranibizumab
- Comparator
- Intravitreal Injection with Ranibizumab 0.5mg
- Outcomes measured
- Time Until a Participant First Requires the Implant Refill According to Protocol-Defined Refill Criteria — Baseline up…; Change From Baseline in Best Corrected Visual Acuity (BCVA) Averaged At Month 9 and 10 — Baseline, Months 9, 10; Change From Baseline in BCVA Over Time — Baseline up to Month 10; Adjusted Average Change From Baseline in BCVA Over Time (MMRM Analysis) — Baseline up to Month 10; Change From Baseline in Central Foveal Thickness (CFT) Over Time as Assessed on Spectral Domain-Optical Coherence Tomog…; Number of Implant Clogging at Month 9 — Month 9; Observed Maximum Serum Concentration (Cmax) of Ranibizumab — Predose (0 hour) on Day 1 up to 38 months; Area Under the Concentration-Time Curve From Dosing to Last Observation (AUClast) of Ranibizumab — Predose (0 hour) on…; Time to Maximum Concentration (Tmax) of Ranibizumab — Predose (0 hour) on Day 1 up to 38 months; Terminal Half-Life (t1/2) of Ranibizumab — Predose (0 hour) on Day 1 up to 38 months; Observed Steady-State Serum Concentration at the End of a Dosing Interval (Ctrough) of Ranibizumab — Predose (0 hour) o…; Number of Participants With Ocular and Non-Ocular Adverse Events (AEs) and Serious AEs (SAEs) — Baseline up to approxim…; Percentage of Participants With Positive Serum Antibodies to Ranibizumab — Baseline up to 38 months
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Title supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.